LYLin-Cheng Yang

Lin-Cheng Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lin-Cheng Yang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Chung-Ren Lin

    Department of Anesthesiology, Chang Gung Memorial Hospital-Kaohsiung Medical Centre, Chang Gung University College of Medicine, Kaohsiung, Taiwan

    4 shared publications
  • Cheng-Yuan Lu

    Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Hsien, Taiwan

    3 shared publications
  • Ping-Heng Tan

    Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Hsien, Taiwan

    2 shared publications
  • Sheng-Han Lin

    Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Hsien, Taiwan

    2 shared publications
  • A. K. Chou

    Anesthesiology Research Laboratory, Kaohsiung Chang Gung Memorial Hospital, Taiwan and

    1 shared publication
  • An-Kuo Chou

    Anesthesiology Research Laboratory, Chang Gung Memorial Hospital, Kaohsiung, Taiwan

    1 shared publication

Latest Publications

  • Open Access

    Inhibition of Corneal Neovascularization with the Combination of Bevacizumab and Plasmid Pigment Epithelium-Derived Factor-Synthetic Amphiphile INTeraction-18 (p-PEDF-SAINT-18) Vector in a Rat Corneal Experimental Angiogenesis Model

    by Chien-Neng Kuo, Chung-Yi Chen, San-Ni Chen, Lin-Cheng Yang, Li-Ju Lai, Chien-Hsiung Lai, Miao-Fen Chen, Chia-Hui Hung, Ching-Hsein Chen

    Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonal antibody to VEGF. PEDF, a 50-kDa glycoprotein, has demonstrated anti-vasopermeability properties. In this study, we demonstrated that the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) has a favorable antiangiogenic effect on corneal NV. Four groups (Group A: 0 μg + 0 μg, B: 0.1 μg + 0.1 μg, C: 1 μg + 1 μg, and D: 10 μg + 10 μg) of bevacizumab + p-PEDF-SAINT-18 were prepared and implanted into the rat subconjunctival substantia propria 1.5 mm from the limbus on the temporal side. Then, 1 μg of p-bFGF-SAINT-18 was prepared and implanted into the rat corneal stroma 1.5 mm from the limbus on the same side. The inhibition of NV was observed and quantified from days 1 to 60. Biomicroscopic examination, western blot analysis and immunohistochemistry were used to analyze the 18-kDa bFGF, 50-kDa PEDF and VEGF protein expression. No inhibition activity for normal limbal vessels was noted. Subconjunctival injection with the combination of bevacizumab and p-PEDF-SAINT-18 successfully inhibited corneal NV. The bFGF and PEDF genes were successfully expressed as shown by western blot analysis, and a mild immune response to HLA-DR was shown by immunohistochemistry. We concluded that the combination of bevacizumab and p-PEDF-SAINT-18 may have more potent and prolonged antiangiogenic effects, making it possible to reduce the frequency of subconjunctival.Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonalantibody to VEGF. PEDF, a 50-kDa glycoprotein, has demonstrated anti-vasopermeabilityproperties. In this study, we demonstrated that the combination of bevacizumaband plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18(p-PEDF-SAINT-18) has a favorable antiangiogenic effect on corneal NV. Four groups(Group A: 0 μg + 0 μg, B: 0.1 μg + 0.1 μg, C: 1 μg + 1 μg, and D: 10 μg + 10 μg) ofbevacizumab + p-PEDF-SAINT-18 were prepared and implanted into the ratsubconjunctival substantia propria 1.5 mm from the limbus on the temporal side. Then, 1 μgof p-bFGF-SAINT-18 was prepared and implanted into the rat corneal stroma 1.5 mm fromthe limbus on the same side. The inhibition of NV was observed and quantified from days1 to 60. Biomicroscopic examination, western blot analysis and immunohistochemistry wereused to analyze the 18-kDa bFGF, 50-kDa PEDF and VEGF protein expression. Noinhibition activity for normal limbal vessels was noted. Subconjunctival injection with thecombination of bevacizumab and p-PEDF-SAINT-18 successfully inhibited corneal NV.The bFGF and PEDF genes were successfully expressed as shown by western blot analysis,and a mild immune response to HLA-DR was shown by immunohistochemistry. Weconcluded that the combination of bevacizumab and p-PEDF-SAINT-18 may have morepotent and prolonged antiangiogenic effects, making it possible to reduce the frequency ofsubconjunctival bevacizumab administration combined with a relatively safe profile andlow toxicity.


    • 1 August 2004
      • Vol. 25  (8) , 1027-30

    Intrathecal cdk5 inhibitor, roscovitine, attenuates morphine antinociceptive tolerance in rats.

    by Cheng-Haung Wang, Tsung-Hsing Lee, Yi-Jung Tsai, Jong-Kang Liu, Yann-Jang Chen, Lin-Cheng Yang, Cheng-Yuang Lu

    To investigate the effect of cyclin-dependent kinase 5 (Cdk5) inhibitor roscovitine on the morphine antinociceptive tolerance development in rats. Tail-flick test as pain threshold measurement and intrathecal injection techniques were used. Intrathecal roscovitine infusion alone produced an antinociceptive effect. Tolerance was induced by continuous intrathecal infusion of morphine 5 microg/h for 5 d. Co-administration of intrathecal roscovitine 1 microg/h for 5 d enhanced the morphine antinociceptive effect in tolerant rats. It also caused a shift in the morphine antinociceptive dose-response curve to the left when co-administered with morphine during tolerance induction, and caused a 67 % reduction in the increase in the ED50 of morphine (dose producing 50 % of the maximum response). Cdk5 modulation is involved in the antinociceptive tolerance of morphine. Intrathecal roscovitine administration could attenuate this tolerance development.


    • 1 June 2003
      • Vol. 41  (2) , 71-5

    Lidocaine: the optimal timing of intravenous administration in attenuation of increase of intraocular pressure during tracheal intubation.

    by Yi-Ming Wang, Kwan-Chi Chung, Hsiao-Feng Lu, Yu-Wei Huang, Kun-Chen Lin, Lin-Cheng Yang, Chung-Ren Lin

    This study was designed to examine the optimal timing of intravenous lidocaine in attenuation of increase of intraocular pressure in response to laryngoscopy and tracheal intubation during induction of anesthesia. One hundred and thirty five adult patients of ASA class I, aged between 20-35 years, undergoing surgical procedures irrelevant to ophthalmology were enrolled for study. Patients were randomly assigned to one of five groups. In group II, III, IV and V the patients received intravenous injection of lidocaine (2 mg/kg), 1, 3, 5, 10 min before tracheal intubation, respectively. Group I in which patients did not receive lidocaine served as the control group. In patients of groups I, IV and V, the intraocular pressure increased significantly after intubation, whereas in those of groups II and III, the intraocular pressure did not. All patients in the five groups showed concomitantly a surge of blood pressure, but the magnitude of increase was smallest in group III in comparison with the other groups. The values of systolic and diastolic pressures 1 min after intubation were significantly less in groups III and IV than in the control group. In healthy patients aged between 20 and 35 the most optimal time of administration of intravenous lidocaine to attenuate the increase of intraocular pressure seemed to be the space between 1 to 3 min before laryngoscopy and tracheal intubation.


  • Open Access

    Intramuscular electroporation with the pro-opiomelanocortin gene in rat adjuvant arthritis

    by I-Chuan Chuang, Chien-Ming Jhao, Chih-Hsun Yang, Hsien-Chang Chang, Chien-Wen Wang, Cheng-Yuan Lu, Yao-Jen Chang, Sheng-Han Lin, Pao-Lin Huang, Lin-Cheng Yang

    Endogenous opioid peptides have an essential role in the intrinsic modulation and control of inflammatory pain, which could be therapeutically useful. In this study, we established a muscular electroporation method for the gene transfer of pro-opiomelanocortin (POMC) in vivo and investigated its effect on inflammatory pain in a rat model of rheumatoid arthritis. The gene encoding human POMC was inserted into a modified pCMV plasmid, and 0–200 μg of the plasmid-POMC DNA construct was transferred into the tibialis anterior muscle of rats treated with complete Freund's adjuvant (CFA) with or without POMC gene transfer by the electroporation method. The safety and efficiency of the gene transfer was assessed with the following parameters: thermal hyperalgesia, serum adrenocorticotropic hormone (ACTH) and endorphin levels, paw swelling and muscle endorphin levels at 1, 2 and 3 weeks after electroporation. Serum ACTH and endorphin levels of the group into which the gene encoding POMC had been transferred were increased to about 13–14-fold those of the normal control. These levels peaked 1 week after electroporation and significantly decreased 2 weeks after electroporation. Rats that had received the gene encoding POMC had less thermal hypersensitivity and paw swelling than the non-gene-transferred group at days 3, 5 and 7 after injection with CFA. Our promising results showed that transfer of the gene encoding POMC by electroporation is a new and effective method for its expression in vivo, and the analgesic effects of POMC cDNA with electroporation in a rat model of rheumatoid arthritis are reversed by naloxone.


  • Inhibition of experimental angiogenesis of cornea by somatostatin

    by Pei-Chang Wu, Chi-Chang Liu, Chih-Hsin Chen, Hsi-Kung Kou, Su-Chin Shen, Cheng-Yuan Lu, Wen-Ying Chou, Ming-Tse Sung, Lin-Cheng Yang

    Background. This study evaluated the inhibitory activity of somatostatin 14 on the angiogenesis of cornea in vivo. Methods. Corneal neovascularization was induced with a pellet containing 90 ng of basic fibroblast growth factor (bFGF) in a rat corneal pocket model. Three kinds of pellets were made containing bFGF plus somatostatin (SST) 0 ng, 20 ng and 200 ng for the control group, group 1 and group 2, respectively. Neovascularization was observed biomicroscopically from day 4 to day 8, and the corneas were then examined for changes in histology. Quantitation of angiogenesis in the cornea was accomplished by caliper and image analysis. Results. The 200-ng dose of SST showed significant inhibition of both length and area of neovascularization on day 7 (0.62±0.11 mm vs 1.29±0.16 mm, 0.50±0.16 mm2 vs 1.35±0.29mm2, group 2 vs control; P <0.05). The 20 ng of somatostatin did not demonstrate any significant inhibition of neovascularization compared with the control group. Conclusion. Our study demonstrated that SST 14 can reduce bFGF-induced corneal angiogenesis. This shows the potential value of somatostatin in the treatment of corneal neovascularization.


  • Effect of pretreatment with ketorolac on propofol injection pain

    by Y. W. Huang, H. Buerkle, T. H. Lee, C. Y. Lu, C. R. Lin, S. H. Lin, A. K. Chou, R. Muhammad, L. C. Yang

    Background:  Pain on injection is still a major problem with propofol. We performed this study to compare different doses of intravenous (i.v.) ketorolac with and without venous occlusion and its effect on the incidence and the severity of the pain after propofol injection.Methods: We conducted a prospective, randomized and double‐blind study of 180 patients (20–60 years of age.) scheduled to undergo elective surgery. Six groups of patients were generated: group A received normal saline (NS) 2 ml i.v.; groups B, C, D received ketorolac 10 mg in 2 ml NS with venous occlusion (VO) and a subsequent propofol injection at either 30, 60 or 120 s; groups E and F received ketorolac 15 mg and 30 mg in 2 ml NS and propofol was injected after 60 s. The pain perception was assessed during injection of propofol in all patients.Result:  The incidence of propofol‐associated injection pain was for A: 46.7%; B: 43.4%; C: 23.3%; D:16.7%; E: 20%, and F: 10%. The incidence of pain following propofol injection was reduced by i.v. ketorolac 10 mg with venous occlusion for 120 s. Furthermore, i.v. ketorolac 15 mg and 30 mg but not 10 mg following propofol injection after 60 s without venous occlusion revealed significant pain reduction when compared to saline group. There was no difference in venous sequelae at 7 days postoperatively between the groups.Conclusion: Our results suggested that pretreatment with i.v. 15 and 30 mg ketorolac reduces pain following propofol injection. Moreover, pretreatment with i.v. ketorolac 10 mg with venous occlusion for 120 s achieves the same pain relief effect.


  • Changes in the levels of nitric oxide synthase and protein kinase C gamma following kainic acid receptor activation in the rat spinal cord.

    by Zhi-Hong Wen, Chih-Shung Wong, Chung-Ren Lin, An-Kuo Chou, Ping-Heng Tan, Yi-Chen Chang, Cheng-Hsing Kao, Tain-Junn Cheng, Lin-Cheng Yang